Leishmaniasis Visceralis

01Pathophysiology

Visceral leishmaniasis begins when a female Phlebotomine sandfly injects promastigotes (the flagellated, motile form of the parasite) into the skin during a blood meal. These promastigotes are rapidly phagocytosed by local macrophages. Once inside the macrophage phagolysosome, the promastigotes transform into amastigotes, the non-flagellated, obligate intracellular form. Amastigotes are uniquely adapted to survive the acidic, enzymatic environment inside macrophages by neutralizing reactive oxygen species and inhibiting phagolysosomal fusion. This is a critical concept: the parasite hijacks the very cells meant to destroy it.

The amastigotes replicate within macrophages until the host cell bursts, releasing parasites that are taken up by new macrophages. This cycle leads to progressive infiltration of the reticuloendothelial system (RES), meaning the organs richest in macrophages: the spleen, liver, bone marrow, and lymph nodes. The relentless parasitization of these organs explains the hallmark clinical findings.

Splenomegaly is the most prominent finding and results from both massive expansion of splenic macrophages loaded with amastigotes and compensatory extramedullary hematopoiesis as the bone marrow becomes progressively infiltrated and dysfunctional. The spleen can become enormous, often crossing the midline.

Pancytopenia occurs through a dual mechanism: (1) bone marrow infiltration by parasitized macrophages directly suppresses hematopoiesis, and (2) hypersplenism from the enlarged spleen causes peripheral destruction and sequestration of all cell lines (red cells, white cells, and platelets).

The reversed A/G ratio is explained by a vigorous but ineffective polyclonal B-cell activation. The immune system mounts a strong humoral (Th2-dominant) response, producing large amounts of immunoglobulins (polyclonal hypergammaglobulinemia), but this antibody response does not clear intracellular amastigotes. Simultaneously, hepatic dysfunction and protein-losing enteropathy cause hypoalbuminemia. The combination produces the classic laboratory finding of a reversed A/G ratio.

Skin darkening (hyperpigmentation), which gives the disease its Hindi name "kala-azar" (black fever), is attributed to adrenal gland involvement and increased melanocyte-stimulating hormone activity, though the exact mechanism is not completely understood.

A critical immunological point: effective clearance of Leishmania requires a Th1 (cell-mediated) immune response with activation of macrophages by interferon-gamma. In visceral leishmaniasis, the immune response is skewed toward a Th2 response, which produces antibodies but fails to activate macrophages for intracellular killing. This is why the leishmanin (Montenegro) skin test, a delayed-type hypersensitivity test measuring Th1 function, is negative during active disease but converts to positive after successful treatment and recovery. This fact is frequently tested.

02Classification and Clinical Manifestation

While leishmaniasis is broadly classified into cutaneous, mucocutaneous, and visceral forms, the following table focuses on the clinical spectrum of visceral disease and its sequelae.

Key Clinical Features by System

03Diagnostic Workup

The approach to diagnosing visceral leishmaniasis follows a logical sequence driven by clinical suspicion and available resources.

Step 1: Clinical Suspicion. Any patient from an endemic region presenting with the triad of prolonged fever, massive splenomegaly, and pancytopenia should trigger suspicion for visceral leishmaniasis. This clinical picture, combined with wasting and a reversed A/G ratio, is the classic vignette presentation.

Step 2: Serological Screening (Best Initial Test). The rK39 rapid test is the recommended first-line diagnostic tool. It is inexpensive, fast (results in 10-20 minutes), and performs well in symptomatic patients from endemic areas (sensitivity >90% in the Indian subcontinent). However, there are important limitations: (1) it remains positive for years after cure, so it cannot distinguish active disease from past infection in endemic populations; (2) in HIV-coinfected patients, sensitivity drops because of impaired antibody production, making serological tests unreliable.

Step 3: Parasitological Confirmation (Gold Standard). Definitive diagnosis requires demonstration of amastigotes on a Giemsa-stained tissue aspirate. The key decision is which tissue to aspirate:

• Splenic aspirate: Highest sensitivity (>95%), but carries a risk of life-threatening hemorrhage, particularly in patients with thrombocytopenia and coagulopathy. Should only be performed in facilities with surgical backup and when platelet counts are adequate.

• Bone marrow aspirate: Safer and most commonly used in practice; sensitivity approximately 60-85%. This is the standard choice when splenic aspirate is not feasible.

• Lymph node aspirate: Least invasive but also least sensitive (approximately 50-60%).

On microscopy, the examiner looks for Leishman-Donovan (LD) bodies, which are round or oval amastigotes (2-4 micrometers) located within the cytoplasm of macrophages. Each amastigote contains a nucleus and a rod-shaped kinetoplast, a finding that helps differentiate them from other intracellular organisms such as Histoplasma capsulatum (which lacks a kinetoplast).

Step 4: Molecular Testing. PCR is increasingly used, particularly in HIV-coinfected patients where serology is unreliable and parasite loads in the blood are often high enough for detection. PCR can also be used to monitor treatment response and detect relapse.

A frequently tested pearl: the leishmanin skin test is NOT useful for diagnosing active visceral disease because it is negative during illness. It only becomes positive after successful treatment and is used epidemiologically or as a marker of cure, not as a diagnostic tool.

04Management and Treatment

Acute Treatment

The cornerstone of visceral leishmaniasis treatment is liposomal amphotericin B, which has become the preferred agent globally due to its high efficacy, favorable safety profile compared to conventional amphotericin B, and the growing problem of antimonial resistance, especially in the Indian subcontinent. Its mechanism involves binding to ergosterol in the parasite cell membrane, causing pore formation and cell death.

In the Indian subcontinent, a single intravenous dose of 10 mg/kg of liposomal amphotericin B achieves cure rates exceeding 95%. This single-dose protocol is transformative for resource-limited settings because it eliminates the need for prolonged hospitalization. In East Africa and other regions, higher total doses (up to 30 mg/kg) administered over multiple days are required due to differences in parasite species and drug sensitivity.

Miltefosine is notable as the first effective oral agent for visceral leishmaniasis. It is dosed at 2.5 mg/kg/day (maximum 150 mg/day) for 28 days. Its main advantages are oral administration and outpatient feasibility. However, it has two critical limitations: (1) it is teratogenic and absolutely contraindicated in pregnancy, and women of childbearing age must use reliable contraception during and for 5 months after treatment; (2) its relatively long treatment course leads to adherence challenges, and monotherapy resistance is an emerging concern.

Pentavalent antimonials (sodium stibogluconate, meglumine antimoniate) were historically first-line and are still used in some regions (East Africa, Latin America). They are administered at 20 mg Sb(V)/kg/day by IV or IM injection for 28-30 days. Their use has declined because of significant toxicity (cardiotoxicity with prolonged QTc, pancreatitis, hepatotoxicity) and high resistance rates in the Indian subcontinent (up to 60% in Bihar, India).

Paromomycin (aminosidine), an aminoglycoside, is given at 15 mg/kg/day IM for 21 days. It is most commonly used in combination with sodium stibogluconate in East Africa to shorten treatment duration and reduce resistance emergence.

Supportive Care

Supportive measures are critical and often determine outcomes. Patients commonly require treatment for nutritional deficiency, correction of anemia (transfusions if severe), and management of secondary infections (pneumonia, tuberculosis, and dysentery are the leading causes of death in untreated or undertreated patients). Co-existing infections must be aggressively identified and treated.

HIV-Coinfected Patients

This population presents unique challenges. Relapse rates are high (up to 60% within 12 months), serological tests may be falsely negative, and presentations are atypical. ART initiation is essential, as immune reconstitution is the single most important factor in preventing relapse. Secondary prophylaxis with liposomal amphotericin B (e.g., 3-5 mg/kg IV every 2-4 weeks) should be continued until the $CD4CD4$ count is sustained above 200 cells/microL for at least 6 months on ART.

Post-Kala-Azar Dermal Leishmaniasis (PKDL)

PKDL develops in a subset of patients after treatment, particularly in the Indian subcontinent and Sudan. Treatment is indicated because these patients serve as a parasite reservoir for ongoing transmission. Management involves liposomal amphotericin B or miltefosine, depending on severity and geographic context.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on visceral leishmaniasis questions falls into several categories.

Confusing the skin test with a diagnostic tool. A frequently encountered trap is selecting the leishmanin (Montenegro) skin test as the answer for diagnosing active visceral leishmaniasis. This test measures delayed-type (Th1) hypersensitivity and is negative during active disease because the immune response is Th2-dominant. It only becomes positive after cure. Students who associate "skin test" with "diagnosis" will fall for this distractor.

Mixing up the parasite forms. Exam questions may test whether the student knows that the amastigote (non-flagellated, intracellular form) is found in the human host, while the promastigote (flagellated, extracellular form) is found in the sandfly vector. Reversing these is a common error.

Confusing Histoplasma with Leishmania on biopsy. Both appear as small, round intracellular organisms within macrophages. The key discriminator is the kinetoplast, a darkly staining, rod-shaped structure adjacent to the nucleus, which is present in Leishmania amastigotes and absent in Histoplasma yeast. If the vignette describes intracellular organisms with a kinetoplast, the answer is leishmaniasis.

Selecting antimonials in an Indian subcontinent vignette. Because of widespread resistance in the Indian subcontinent (particularly in Bihar), the correct first-line treatment is liposomal amphotericin B, not sodium stibogluconate. Students who default to older guidelines or rote-memorized drug lists will select the wrong agent.

Forgetting miltefosine's teratogenicity. When a vignette involves a pregnant woman or a woman of childbearing age without contraception, miltefosine must not be selected. Liposomal amphotericin B is the safe choice in pregnancy.

Overlooking PKDL as a public health concern. Questions may frame PKDL not as a clinical emergency for the individual patient but as a disease transmission question. The tested concept is that PKDL patients serve as a reservoir host, maintaining the parasite in the community and fueling ongoing sandfly-to-human transmission even after the visceral disease has been treated.

The core competency being tested across visceral leishmaniasis questions is the ability to recognize a classic clinical syndrome (prolonged fever, massive splenomegaly, pancytopenia, reversed A/G ratio in a patient from an endemic area), select the correct diagnostic sequence (rK39 for screening, tissue aspirate for confirmation), and match the treatment to the clinical context (liposomal amphotericin B as first-line, with awareness of contraindications and regional resistance patterns).